Back to Trades
Draghia-Akli Ruxandra
EVPResearch & DevelopmentCIK 0002041719
Largest Purchase
No open-market purchases in the recent filings.
Profile
- Filings
- 3
- Buy transactions
- 0
- Sell transactions
- 0
- Companies
- 1
- Active
- 2025–2026
Draghia-Akli Ruxandra, EVP, Research & Development, accounts for 3 disclosed filings worth $1.4M, all concentrated in NOVAVAX INC (NVAX), active 2025–2026. Data is sourced from official SEC Form 3, 4, and 5 filings.
Associated Companies
Trading History
3 loaded
| Mar 9 | NVAX NOVAVAX INC | Draghia-Akli Ruxandra | EVP, Research & Development | Award | $0 |
| Mar 5 | NVAX NOVAVAX INC | Draghia-Akli Ruxandra | EVP, Research & Development | Exercise | $1.4M |
| Nov 13 | NVAX NOVAVAX INC | Draghia-Akli Ruxandra | Section 16 | Exercise | $44.8K |
3 filings